Quantcast
Last updated on April 21, 2014 at 12:45 EDT

MiMedx Group’s Chairman, Parker H. “Pete” Petit, Is Inducted Into the National Academy of Engineering

October 20, 2011

KENNESAW, Ga., Oct. 20, 2011 /PRNewswire/ — MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its Chairman and CEO, Parker H. “Pete” Petit, has been inducted into the National Academy of Engineering.

Election to the National Academy of Engineering is among the highest professional distinctions accorded to an individual. Academy membership honors those who have made outstanding contributions to “engineering research, practice, or education, including, where appropriate, significant contributions to the engineering literature,” and to the “pioneering of new and developing fields of technology, making major advancements in traditional fields of engineering, or developing/implementing innovative approaches to engineering education.”

Petit’s principal engineering accomplishments recognized by the National Academy of Engineering are “for developing and manufacturing the first home Sudden Infant Death Syndrome monitor and for pioneering pediatric home health care.” Petit founded Healthdyne and developed the first SIDS monitor for home use in the 1970s; and in the 1980s, pioneered high tech pediatric home health care.

About MiMedx

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials” is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix(TM) and CollaFix(TM), and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 35,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.

SOURCE MiMedx Group, Inc.


Source: PR Newswire